Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL27887046 | 0.98 | PTGDR2 (0.57) | PTGDR2ACHESYKMAOAMAOB | |
| SCHEMBL14446041 | 0.88 | ACHE (0.58) | PTGDR2ACHESYKMAOAMAOB | |
| SCHEMBL15906120 | 0.86 | ACHE (0.52) | PTGDR2ACHESYKALDH1A1SMN1; SMN2 | |
| SCHEMBL14003484 | 0.86 | SYK (0.54) | PTGDR2ACHESYKALDH1A1SMN1; SMN2 | |
| SCHEMBL10898179 | 0.86 | PTGDR2 (0.60) | PTGDR2ACHESYKMAOBALDH1A1 | |
| SCHEMBL11962286 | 0.84 | ACHE (0.54) | PTGDR2ACHEALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12326181 | 0.83 | MAOA (0.53) | MAOAMAOBALDH1A1KDM4EMEN1 | |
| SCHEMBL1298462 | 0.82 | PTGDR2 (0.57) | PTGDR2ACHESYKMAOBALDH1A1 | |
| SCHEMBL14363373 | 0.82 | SYK (0.61) | ACHESYKMAOBALDH1A1KDM4E | |
| SCHEMBL7875685 | 0.82 | ACHE (0.55) | ACHESYKMAOBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010046801-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-04-29 | — | — | WO | claimed |
| CN-113214178-B | 3-aryl substituted anthranilic anhydride derivative and preparation method thereof | 广东工业大学 | 2022-05-13 | — | — | CN | disclosed |
| EP-3915990-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2021-12-01 | — | — | EP | disclosed |
| EP-3066072-B1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIV KANSAS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2019129783-A9 | METHOD FOR PREPARING 2,7-OCTADIENE-1-OL | TECHNOLOGIES MOLECULAIRES TECMO (FR) | 2019-09-12 | — | — | WO | disclosed |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMA (US) | 2017-05-25 | — | — | US | disclosed |
| US-9511067-B2 | Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| EP-1498178-A2 | Transition metal complex, process for producing the same, olefin polymerization catalyst containing the transition metal complex and process for producing olefin polymers | Sumitomo Chemical Company, Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-0963990-B1 | PROCESS FOR PRODUCING CYCLOPENTADIENYL METAL SALTS AND PROCESS FOR PRODUCING CYCLOPENTADIENE DERIVATIVES BY UTILIZING THE SAME | SUMITOMO CHEMICAL CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| EP-0842939-B1 | OLEFIN POLYMERIZATION CATALYST CONTAINING A TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING OLEFIN POLYMERS | SUMITOMO CHEMICAL CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6329478-B1 | SOLUBILITY IN SATURATED HYDROCARBON SOLVENTS | SUMITMO CHEMICAL COMPANY, LIMITED | 2001-12-11 | — | — | US | disclosed |
| US-6197990-B1 | REACTING CYCLOPENTADIENE AND METAL HYDRIDE IN PRESENCE OF AMINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0963990-A1 | PROCESS FOR PRODUCING CYCLOPENTADIENYL METAL SALTS AND PROCESS FOR PRODUCING CYCLOPENTADIENE DERIVATIVES BY UTILIZING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-12-15 | — | — | EP | disclosed |
| EP-0842939-A1 | TRANSITION METAL COMPLEX, PROCESS FOR THE PREPARATION THEREOF, POLYMERIZATION CATALYST FOR OLEFINS CONTAINING THE COMPLEX, AND PROCESS FOR PRODUCING OLEFIN POLYMERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
| US-4318783-A | Process for the preparation of optionally substituted benzaldehyde dialkyl acetals | BAYER AKTIENGESELLSCHAFT (DE) | 1982-03-09 | — | — | US | disclosed |
| EP-0012240-B1 | PROCESS FOR MANUFACTURING OF OPTIONALLY SUBSTITUTED BENZALDEHYD-DIALKYL ACETALS | BAYER AG (DE) | 1982-01-20 | — | — | EP | disclosed |
| EP-0012240-A2 | Process for manufacturing of optionally substituted benzaldehyd-dialkyl acetals | BAYER AG (DE) | 1980-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | PTGDR2 607/4885ACHE 1784/4885SYK 4302/4885 |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | PTGDR2 2749/4885ACHE 4046/4885SYK 1807/4885 |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | PTGDR2 1851/4885ACHE 4813/4885SYK 3301/4885 |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | PTGDR2 1851/4885ACHE 4813/4885SYK 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.